• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Animal Model Market Analysis

    ID: MRFR/Pharma/8231-HCR
    140 Pages
    Rahul Gotadki
    September 2025

    Animal Model Market Research Report Information By Animal Type (Pigs, Cats, and Mice), By Technology (CRISPR, Microinjection, and Embryonic Stem Cell Injection), By Application (Research & Development, Production, and Quality Control), By End-User (Research Institutes, Educational Institutes, Pharmaceutical Companies, and Contract Research Organizations), And By Region (North America, Europ...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Animal Model Market Research Report - Forecast till 2034 Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Analysis

    Animal Model Market (Global, 2025)

    Introduction

    In the midst of the burgeoning demand for new drugs and the increasing prevalence of chronic diseases, the animal model market is set to play a crucial role in advancing biomedical research and drug development. In order to understand complex biological processes and to test the efficacy and safety of new drugs, the use of animal models has become indispensable. These models are invaluable in providing insights into human physiology and pathophysiology and are critical in enabling the translation of laboratory findings into clinical applications. In addition, ethical considerations concerning animal research are driving the development of more refined and humane methods, which are shaping the future of the animal model market. Moreover, the market is characterized by a complex interplay between scientific advances, regulatory frameworks, and technological innovations, which together are driving the evolution of animal models in research settings.

    PESTLE Analysis

    Political
    In 2025, the political climate of the animal model market is dominated by the regulation of animal experimentation. The European Union has established the directive 2010/63 / EC, which requires that a minimum of 80% of all animal experiments comply with the principles of the 3Rs. This directive has an effect on the 12 million animals used in research in the EU each year and is followed by a rise in scrutiny and compliance costs for companies operating in this sector.
    Economic
    In 2025, the market for animal models will be characterized by an increased investment in biotechnology and pharmaceutical research. In the United States, the National Institutes of Health (NIH) will allocate 42 billion dollars for biomedical research in 2024, an increase of 5 percent over the previous year. This will support the development and use of animal models, and will increase the demand for high-quality research products and services. In addition, the world's spending on animal testing is expected to reach $ 3.5 billion in 2025, reflecting the growing use of animal models in drug development.
    Social
    Social attitudes towards animal experimentation are changing, and are becoming more and more ethically minded and concerned with the well-being of animals. A poll in 2024 showed that 67% of Americans supported stricter regulations on animal experimentation, a sign of a shift in public opinion. This change in public opinion is forcing companies in the animal model market to adopt more humane practices and to invest in alternative methods, such as in vitro testing, in order to meet consumer expectations and ethical standards.
    Technological
    In the animal model market, technological advances are playing an important role. Artificial intelligence (AI) and machine learning are expected to increase the efficiency of animal studies by 2025. In fact, AI-based platforms are expected to reduce the time needed for data analysis by up to 30%, enabling faster insights into data. Also, genetic engineering innovations, such as CRISPR, are enabling the development of more accurate animal models. These developments are expected to increase the accuracy of preclinical studies.
    Legal
    The legal framework regulating the use of animals as models is becoming more and more strict. In 2024 the United States passed a law that prohibited the use of animals as models. The Animal Protection Act was amended with stricter penalties for infringements, with fines of up to $250,000 for noncompliance. This legal framework makes it necessary for companies to invest in compliance and training to avoid legal consequences. Also, the 3Rs are being increasingly closely scrutinized, with regulatory agencies carrying out regular audits of laboratories to ensure compliance with ethical standards.
    Environmental
    A recent trend in the animal model market is to be increasingly concerned with the environment, in particular the viability of research practices. It is estimated that by 2025, some 1.4 million tons of waste will be produced annually by animal research laboratories, and this has led to calls for more sustainable waste management practices. Green initiatives such as the reduction of the use of hazardous materials and the increase of the use of recycled materials are being increasingly adopted by companies to reduce their impact on the environment. Also, the development of alternative methods for testing products is expected to help reduce the overall impact of animal research on the environment.

    Porter's Five Forces

    Threat of New Entrants
    The Animal-Mascot Market in 2025 is characterized by moderate entry barriers. Although initial investment in research and development, regulatory compliance, and ethical issues can be high, the growing demand for animal models in drug development and research offers opportunities for new entrants. However, established companies with a strong brand and wide network can be a challenge to new entrants.
    Bargaining Power of Suppliers
    The bargaining power of suppliers in the animal market is generally low because of the availability of many sources of animal models and related services. The large number of suppliers reduces the influence of a single supplier. Furthermore, advances in technology and breeding methods have increased the supply of animal models, which further reduces the bargaining power of suppliers.
    Bargaining Power of Buyers
    The buyers of Animal Models in the market have considerable power over suppliers, primarily because of the presence of several alternatives and the critical nature of their research needs. Moreover, pharmaceutical companies, academic institutions and biotechnology companies have particular requirements, and can therefore negotiate the best prices and terms. Further, the growing emphasis on cost-effectiveness in research gives them an even greater incentive to seek the best offer.
    Threat of Substitutes
    The threat of substitutes in the animal-testing market is moderate, as alternative research methods, such as in vitro tests, computer simulations and synthetic biology, gain ground. But animals still offer unique insights into complex biological systems that cannot be fully replicated by alternatives. The threat of substitutes may grow as technology develops, but animal models are still essential for some research.
    Competitive Rivalry
    Competition in the Animal Models market is high, owing to the presence of a large number of established players and the constant innovation in animal model development. Competition is mainly driven by product differentiation, quality improvement and customer service. The fast-paced developments in biotechnology and the increasing demand for animal models from various research fields are putting increasing pressure on existing companies.

    SWOT Analysis

    Strengths

    • Established regulatory frameworks supporting animal research.
    • Diverse range of animal models available for various research needs.
    • Strong investment from pharmaceutical and biotechnology companies.
    • Growing acceptance of animal models in preclinical research.

    Weaknesses

    • Ethical concerns and public opposition to animal testing.
    • High costs associated with breeding and maintaining animal models.
    • Limited availability of certain species for specific research.
    • Variability in animal responses can affect research outcomes.

    Opportunities

    • Advancements in genetic engineering and biotechnology to create better models.
    • Increasing demand for personalized medicine driving research needs.
    • Expansion of research in emerging markets with less stringent regulations.
    • Collaboration opportunities between academia and industry for innovative models.

    Threats

    • Stricter regulations and potential bans on animal testing in some regions.
    • Growing competition from alternative testing methods, such as in vitro and computational models.
    • Public backlash and activism against animal research impacting funding.
    • Economic downturns affecting research budgets and investments.

    Summary

    The Animal Models Market in 2025 is characterized by a strong regulatory support and substantial investment from the pharmaceutical industry, which bolsters its growth. However, the main obstacles are ethical concerns and high operational costs. Opportunities are a technological development and a growing demand for individualized medicine. Threats are the development of alternative research methods and regulatory changes. Strategically focusing on innovation and collaboration will be key to navigating these complexities.

    Market Summary

    As per Market Research Future Analysis, the Animal Model Market was valued at USD 2.78 Billion in 2024 and is projected to grow to USD 5.53 Billion by 2034, with a CAGR of 7.12% from 2025 to 2034. Key drivers include advancements in CRISPR technology and increased use of animal models in various research fields such as biomedical and neurological research. The COVID-19 pandemic has further accelerated the demand for animal models in vaccine and antiviral research, enhancing market growth. Mice are the predominant animal model used, accounting for 95% of laboratory animals, while CRISPR technology leads the market in terms of growth potential. The pharmaceutical sector remains the largest end-user, driven by the need for drug discovery and development.

    Key Market Trends & Highlights

    The Animal Model Market is witnessing significant growth driven by technological advancements and increased research activities.

    • Market Size in 2024: USD 2.78 Billion; Expected to reach USD 5.53 Billion by 2034.
    • CAGR from 2025 to 2034: 7.12%; driven by CRISPR technology and COVID-19 research.
    • Mice account for 95% of laboratory animals; preferred for their biological similarities to humans.
    • Pharmaceutical companies held the largest market share in 2021, emphasizing the importance of animal models in drug development.

    Market Size & Forecast

    2024 Market Size USD 2.78 Billion
    2034 Market Size USD 5.53 Billion
    CAGR (2025-2034) 7.12%
    Largest End User Pharmaceutical Companies.

    Major Players

    Key companies include Horizon Discovery Group plc, Charles River Laboratories International Inc., Transposagen Biopharmaceuticals Inc., and Envigo.

    Market Trends

    Growth in drug discovery and development in the pharmaceutical sector to boost the market growth

    On January 30, 2020, the World Health Organization (WHO) proclaimed the COVID-19 outbreak a public health emergency of significance. A total of 210 countries throughout the world have been impacted by COVID-19. The COVID-19 pandemic is an unprecedented threat to public health. It is projected to significantly affect the market for animal models used in vaccine and antiviral medication research and development. Before conducting human trials, it is crucial to confirm the safety and effectiveness of new entities using a wide number of animal models.

    For instance, according to the WHO, almost 20 vaccines are reportedly being developed internationally for COVID-19. These COVID-19 vaccines are in the preclinical stage, and some have already begun animal testing. The SARS-CoV-2 coronavirus has been replicated in some mouse models, including the 129SvEv, hACE2 transgenic, BALB/c, C57BL/6, and STA1 gene deletion strains (KO). Therefore, during the projection period, COVID-19 infection increased growth and prospects for important companies in animal models.

    Animal models are useful for target identification and validation, toxicity and safety testing, drug screening and lead optimization, and preclinical drug efficacy and safety evaluation. The market is predicted to increase in the next years due to the rise in genetic illnesses on a scale and the expanding research community. To better understand diseases, especially infectious and chronic diseases, animal models of living non-human animals are frequently used. Pharmaceutical firms, academic organizations, and research facilities use these animal models to create new medications, cures, and treatments.

    Animal models are non-human living beings employed in research and experimentation due to their immunology and pathophysiology comparable to people. They have been employed in cellular and histological research as well as the prognosis, diagnosis, treatment, and study of illnesses and the discovery and development of medications. According to the U.S. Department of Agriculture, one hundred million mice, rats, and 1 million other animals were kept in captivity for research and laboratory tests in 2019.

    Animal models that most closely resemble human systems are preferred since using human models for research is controversial on many levels due to the risk to human life, enhanced the animal model market CAGR across the globe in recent years.

    Additionally, academic institutions use histological sections of certain organs for their microscopic research and use models in their labs to demonstrate anatomical dissections. The need for such models is predicted to rise in response to advancements in the education sector, supporting market revenue growth between 2022 and 2030, another factor driving the animal model market revenue growth.

    The development of CRISPR technology as a powerful tool in biomedical research and the growing use of animal models in neurological research, biomedical research, toxicology, genetic research, physiology, cancer research, and xenotransplantationare the key market drivers enhancing market growth.

    The Global Animal Model Market appears to be evolving rapidly, driven by advancements in biotechnology and an increasing emphasis on ethical research practices, which may reshape the landscape of preclinical testing.

    U.S. National Institutes of Health (NIH)

    Animal Model Market Market Drivers

    Market Growth Projections

    Emerging Markets and Globalization

    Emerging markets are increasingly contributing to the Global Animal Model Market Industry as globalization facilitates collaboration and knowledge exchange. Countries in Asia-Pacific and Latin America are witnessing a rise in research activities, driven by both local and international investments. This trend is fostering the development of regional animal model facilities and research institutions, which are essential for advancing scientific knowledge. The expansion of these markets is expected to enhance the overall growth of the industry, as they adopt advanced animal models for research purposes. The globalization of research initiatives is likely to create new opportunities for market players.

    Advancements in Genetic Engineering

    Advancements in genetic engineering techniques, such as CRISPR and gene editing, are significantly influencing the Global Animal Model Market Industry. These technologies enable the creation of more precise and relevant animal models that closely mimic human diseases. This precision enhances the predictability of drug responses, thereby improving the efficiency of preclinical trials. As a result, researchers are increasingly adopting these advanced models, which are expected to drive market growth. The integration of genetically modified organisms into research protocols is likely to contribute to the overall expansion of the market, aligning with the projected growth trajectory leading to 2035.

    Rising Demand for Biopharmaceuticals

    The increasing demand for biopharmaceuticals is a primary driver of the Global Animal Model Market Industry. As the biopharmaceutical sector expands, the need for effective preclinical testing using animal models becomes crucial. In 2024, the market is valued at approximately 2.79 USD Billion, reflecting the industry's reliance on animal models for drug development and safety assessments. This trend is expected to continue, with projections indicating a market growth to 5.93 USD Billion by 2035. The compound annual growth rate (CAGR) of 7.11% from 2025 to 2035 underscores the importance of animal models in facilitating the development of innovative therapies.

    Regulatory Support for Animal Research

    Regulatory support for animal research plays a pivotal role in the Global Animal Model Market Industry. Governments and regulatory bodies are increasingly recognizing the necessity of animal models in the drug development process. This support manifests through guidelines that promote ethical research practices while ensuring the welfare of animals used in studies. Such frameworks facilitate the approval of new drugs and therapies, thereby fostering innovation. As the market evolves, the alignment of regulatory policies with scientific advancements is likely to enhance the credibility and acceptance of animal models, further driving market growth through 2035.

    Increasing Investment in Research and Development

    The surge in investment in research and development (R&D) across various sectors is a significant driver of the Global Animal Model Market Industry. Pharmaceutical and biotechnology companies are allocating substantial resources to R&D to discover new therapies and treatments. This trend is reflected in the growing number of preclinical studies utilizing animal models, which are essential for understanding disease mechanisms and testing drug efficacy. The anticipated growth of the market from 2.79 USD Billion in 2024 to 5.93 USD Billion by 2035 highlights the critical role of R&D investments in shaping the future landscape of animal model applications.

    Market Segment Insights

    Animal Model Animal Type Insights

    The animal model market segmentation, based on animal type, includes pigs, cats, and mice. The mice segment held the majority share in 2021 of the animal model market revenue. About 95% of all laboratory animals are either mice or rats, with mice being the most popular model in academic and pharmaceutical research. Their small size, short lifespan, reproductive cycle, gentle temperament, and docility, and prior understanding of their biology, physiology, anatomy, genetic mapping, and simplicity of making genetically modified mice make them ideal study models.

    Animal Model Technology Insights

    The animal model market segmentation, based on technology, includes CRISPR, microinjection, and embryonic stem cell injection. The CRISPR segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period 2022-2030. A group of DNA sequences known as CRISPR can be discovered in the genomes of prokaryotic organisms like bacteria and archaea. The DNA fragments of bacteriophages that previously infected the prokaryote are where these sequences were derived. During successive infections, they locate and eradicate DNA from similar bacteriophages, positively impacting the market growth.

    Animal Model Application Insights

    The animal model market data has been bifurcated by application into research & development, production, and quality control. The research & development segment dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period 2022-2030. During the projection period, a consistent revenue growth rate is anticipated due to rising demand from laboratories worldwide for toxicity testing and nutritional, immunological, neurological, and genetic studies for basic and applied research.

    Figure 2: Animal Model Market by Application, 2023 & 2030 (USD Billion) 

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Animal Model End User Insights

    Based on End Users, the animal model industry has been segmented into research institutes, educational institutes, pharmaceutical companies, and contract research organizations. Pharmaceutical companies held the largest segment share in 2021. The COVID-19 pandemic has raised the need for animal models in the pharmaceutical industry for clinical research, choosing the best medication candidate from a pool of potential leads, and other purposes. Mice models are employed in high-throughput screening or studies in which thousands of models are quickly examined using automation due to the inexpensive expenses of breeding, reproducing, and administering testing.

    Get more detailed insights about Animal Model Market Research Report - Forecast till 2034

    Regional Insights

    By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. North America Animal Model market accounted for USD 0.90 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. It is anticipated that the COVID-19 pandemic will result in a swift expansion of the pharmaceutical industry, raising demand for pharmaceuticals, vaccines, and monoclonal antibodies in the region's nations and propelling market revenue growth.

    Further, the major countries studied in the market report are: The U.S., Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 3: ANIMAL MODEL MARKET SHARE BY REGION 2023 (%) ANIMAL MODEL MARKET SHARE BY REGION 2021

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Europe animal model market accounts for the second-largest market share. The region's substantial concentration of toxicological, nutritional, immunological, and other medical labs is anticipated to fuel market revenue growth. Further, the Germany animal model market held the largest market share, and the UK animal model market was the fastest-growing market in the European region.

    The Asia-Pacific Animal Model Market is expected to grow at the fastest CAGR from 2022 to 2030. Animal model market revenue is growing due to characteristics such as ease of manipulation, short lifespan, and high reproducibility being adopted in industries across Asia-Pacific. Moreover, the China animal model market held the largest market share, and the India animal model market was the fastest-growing market in the Asia-Pacific region.

    Key Players and Competitive Insights

    Major market players are spending a lot of money on R&D to increase their product lines, which will help the animal model market grow even more. Market participants are also taking various strategic initiatives to grow their footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the animal model industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

    One of the primary business strategies manufacturers adopt in the animal model industry to benefit clients and expand the market sector is manufacturing locally to reduce operating costs. In recent years, the animal model industry has provided some of the most significant benefits. The animal model market major players, such as Horizon Discovery Group plc, Charles River Laboratories International Inc., Transposagen Biopharmaceuticals Inc., and others, are working on expanding the market demand by investing in research and development activities.

    Charles River Laboratories International, Inc. specializes in a range of preclinical and clinical laboratory, gene therapy, and cell therapy services for the pharmaceutical, medical device, and biotechnology industries. In May 2021, a gene therapy contract development and manufacturing organization (CDMO), Vigene Biosciences, was purchased by Charles River for $292.5 million.

    Also, Envigo is a privately held contract research organization and lab animal source that offers live animals and related goods and services to the biotechnology and pharmaceutical industries, as well as to the government, the academic community, and other life science organizations that use animals in testing. In December 2019, the research models division of Horizon Discovery, which offers genetically altered models from its Boyertown, Pennsylvania, and St. Louis, Missouri, facilities, was bought by Envigo.

    Key Companies in the Animal Model Market market include

    Industry Developments

    • Q2 2024: Charles River Laboratories Announces Opening of New Preclinical Research Facility in North Carolina Charles River Laboratories opened a new state-of-the-art preclinical research facility in North Carolina to expand its capacity for animal model-based drug development and testing.
    • Q1 2024: GenOway and Merck KGaA Announce Strategic Partnership to Develop Next-Generation Humanized Mouse Models GenOway entered a strategic partnership with Merck KGaA to co-develop advanced humanized mouse models for immuno-oncology and autoimmune disease research.
    • Q2 2024: Taconic Biosciences Launches New CRISPR-Engineered Rat Model for Neurological Disease Research Taconic Biosciences launched a new CRISPR-engineered rat model designed to accelerate preclinical studies in neurological disorders.
    • Q3 2024: Eurofins Scientific Expands Animal Model Services with Acquisition of Preclinical CRO in Japan Eurofins Scientific acquired a leading Japanese preclinical contract research organization to strengthen its animal model services and global reach.
    • Q2 2024: The Jackson Laboratory Receives NIH Grant to Develop Rare Disease Mouse Models The Jackson Laboratory was awarded a multi-million dollar NIH grant to develop and distribute new mouse models for rare genetic diseases.
    • Q1 2025: Envigo Appoints New CEO to Lead Global Expansion in Animal Model Research Envigo announced the appointment of a new CEO to drive its global expansion and innovation in animal model research services.
    • Q2 2025: Charles River Laboratories Acquires Hera BioLabs to Expand Portfolio of Gene-Edited Animal Models Charles River Laboratories acquired Hera BioLabs, enhancing its portfolio of gene-edited animal models for drug discovery and safety testing.
    • Q1 2024: Biocytogen Raises $60 Million in Series C Funding to Accelerate Development of Humanized Animal Models Biocytogen secured $60 million in Series C funding to expand its pipeline of humanized animal models for pharmaceutical research.
    • Q3 2024: JSR Corporation Announces Strategic Investment in Ozgene to Advance Genetically Modified Animal Model Technologies JSR Corporation made a strategic investment in Ozgene to support the development of next-generation genetically modified animal models.
    • Q2 2025: PerkinElmer Launches New Zebrafish Model Platform for High-Throughput Drug Screening PerkinElmer introduced a new zebrafish model platform aimed at enabling high-throughput drug screening for early-stage pharmaceutical research.
    • Q1 2025: Trans Genic Inc. Wins Major Contract to Supply Custom Animal Models for European Biotech Consortium Trans Genic Inc. secured a significant contract to supply custom animal models to a consortium of European biotech firms for collaborative research projects.
    • Q2 2024: Envigo Opens New Animal Model Production Facility in Germany Envigo opened a new production facility in Germany to meet growing demand for specialized animal models in European biomedical research.

    Future Outlook

    Animal Model Market Future Outlook

    The Global Animal Model Market is projected to grow at a 7.11% CAGR from 2024 to 2035, driven by advancements in biotechnology, increasing R&D investments, and rising demand for personalized medicine.

    New opportunities lie in:

    • Develop innovative animal models for rare diseases to address unmet medical needs.
    • Leverage AI technologies to enhance data analysis in preclinical studies.
    • Expand partnerships with academic institutions for collaborative research initiatives.

    By 2035, the Animal Model Market is expected to be robust, reflecting substantial growth and innovation.

    Market Segmentation

    Animal Model End User Outlook

    • Research Institutes
    • Educational Institutes
    • Pharmaceutical Companies
    • Contract Research Organizations

    Animal Model Regional Outlook

    • US
    • Canada

    Animal Model Technology Outlook

    • CRISPR
    • Microinjection
    • Embryonic Stem Cell Injection

    Animal Model Animal Type Outlook

    • Pigs
    • Cats
    • Mice

    Animal Model Application Outlook

    • Research and Development
    • Production
    • Quality Control

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024    2.78 (USD Billion)
    Market Size 2025    2.98 (USD Billion)
    Market Size 2034    5.53 (USD Billion)
    Compound Annual Growth Rate (CAGR)    7.12 % (2025 - 2034)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2034
    Historical Data 2020 - 2024
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Animal Type, Technology, Application, End User, and Region
    Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
    Countries Covered The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled Horizon Discovery Group plc, Charles River Laboratories International Inc., Transposagen Biopharmaceuticals Inc., Trans Genic Inc, Envigo CRS SA, Eurofins Scientific SE, Crown Bioscience Inc., The Jackson Laboratory, and Genoway SA
    Key Market Opportunities The increasing innovation and research activity using mice models for immune diseases, cancer, rare disease, and other research activities
    Key Market Dynamics Growth in drug discovery and development in the pharmaceutical sector Use of models in basic and applied research

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    How much is the animal model market?

    The animal model market size was valued at USD 2.1 Billion in 2021.

    What is the growth rate of the animal model market?

    The market of animal models is projected to grow at a CAGR of 7.1% during the forecast period 2024-2032.

    Which region held the largest market share in the animal model market?

    North America had the largest share in the market of animal models.

    Who are the key players in the animal model market?

    The key players in the market are Horizon Discovery Group plc, Charles River Laboratories International Inc., Transposagen Biopharmaceuticals Inc., Trans Genic Inc, Envigo CRS SA, Eurofins Scientific SE, Crown Bioscience Inc., The Jackson Laboratory, and Genoway SA.

    Which animal type led the animal model market?

    The mice category dominated the market in 2021.

    Which technology had the largest market share in the animal model market?

    CRISPR had the largest share in the market.

    1. 'Table of Contents
      1. Market Attractiveness Analysis
    2. Global Animal Model Market, by Animal Type
      1. Global Animal Model Market, by Technique
        1. Global Animal
    3. Model Market, by Application
      1. Global Animal Model Market, by End User
      2. Definition
      3. Scope of the Study
        1. Research Objective
        2. Assumptions
        3. Limitations
      4. Overview
      5. Data Mining
      6. Secondary Research
      7. Primary Research
        1. Breakdown of Primary Respondents
      8. Forecasting Techniques
      9. Research
    4. Methodology for Market Size Estimation
      1. Bottom-Up Approach
        1. Top-Down Approach
      2. Data Triangulation
      3. Validation
      4. Overview
      5. Drivers
      6. Restraints
      7. Opportunities
      8. Porter’s Five Forces Analysis
        1. Bargaining Power of Suppliers
    5. Bargaining Power of Buyers
      1. Threat of New Entrants
        1. Threat of Substitutes
        2. Intensity of Rivalry
      2. Value Chain Analysis
        1. R&D and Designing
        2. Manufacturing
        3. Distribution & Sales
        4. Post Sales Services
      3. Impact of COVID
        1. Impact on Market Value in 2020 and 2021
        2. Clinical Trial Impact
        3. Strategies to Overcome the challenges
        4. Impact on Supply Chain
        5. Impact on Pricing
    6. GLOBAL ANIMAL MODEL MARKET, BY ANIMAL TYPE
      1. Overview
      2. Mice
    7. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    8. Forecast, by Country, 2020–2027
      1. Rats
    9. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    10. Forecast, by Country, 2020–2027
      1. Pigs
    11. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    12. Forecast, by Country, 2020–2027
      1. Rabbits
    13. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    14. Forecast, by Country, 2020–2027
      1. Others
    15. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    16. Forecast, by Country, 2020–2027
      1. Overview
      2. CRISPR
    17. Market Estimates & Forecast, by Region, 2020–2027
    18. Market Estimates & Forecast, by Country, 2020–2027
      1. Microinjection Market Estimates
    19. Forecast, by Region, 2020–2027
    20. Market Estimates & Forecast, by Country, 2020–2027
      1. Electroporation Market Estimates
    21. & Forecast, by Region, 2020–2027
    22. Market Estimates & Forecast, by Country, 2020–2027
      1. Others Market Estimates
    23. Forecast, by Region, 2020–2027
    24. Market Estimates & Forecast, by Country, 2020–2027
      1. Overview
      2. Research and Development
    25. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    26. Forecast, by Country, 2020–2027
      1. Cardiovascular
    27. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    28. Forecast, by Country, 2020–2027
      1. Infectious Diseases
    29. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    30. Forecast, by Country, 2020–2027
      1. Metabolic Diseases
    31. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    32. Forecast, by Country, 2020–2027
      1. Immunological Diseases
    33. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    34. Forecast, by Country, 2020–2027
      1. Cancer
    35. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    36. Forecast, by Country, 2020–2027
      1. Diabetes
    37. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    38. Forecast, by Country, 2020–2027
      1. Genetic Diseases
    39. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    40. Forecast, by Country, 2020–2027
      1. Neurological Diseases
    41. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    42. Forecast, by Country, 2020–2027
      1. Others
    43. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    44. Forecast, by Country, 2020–2027
      1. Production and Quality Control
    45. Market Estimates & Forecast, by Region, 2020–2027 Market Estimates
    46. Forecast, by Country, 2020–2027
      1. Overview
      2. Research Institutes Market Estimates
    47. Forecast, by Region, 2020–2027
    48. Market Estimates & Forecast, by Country, 2020–2027
      1. Educational Institutes Market Estimates
    49. Forecast, by Region, 2020–2027
    50. Market Estimates & Forecast, by Country, 2020–2027
      1. Pharmaceutical Companies Market Estimates
    51. Forecast, by Region, 2020–2027
    52. Market Estimates & Forecast, by Country, 2020–2027
      1. Contract Research Organizations Market
    53. Estimates & Forecast, by Region, 2020–2027
    54. Market Estimates & Forecast, by Country, 2020–2027
    55. MODEL MARKET, BY REGION
      1. Overview
      2. Americas
        1. North America
        2. Latin America
      3. Europe
        1. Western Europe
        2. Eastern Europe
      4. Asia-Pacific
        1. Japan
        2. China
        3. India
        4. Australia
        5. South Korea
        6. Rest of Asia-Pacific
      5. Middle East & Africa
        1. Middle East
        2. Africa
      6. Overview
      7. Competitor Dashboard
    56. Major Growth Strategy in the Global Animal Model Market
      1. Competitive Benchmarking
      2. The Leading Player in terms
    57. of Number of Developments in the Global Animal Model Market
      1. Key Developments & Growth Strategies
        1. New Product Launch/Service Deployment
        2. Merger & Acquisition
        3. Joint Ventures
      2. Major Players Financial Matrix & Market Ratio
        1. Sales & Operating Income 2019
    58. Major Players R&D Expenditure 2019
      1. Janvier Labs
        1. Company Overview
        2. Products/Services Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      2. Charles River Laboratories
      3. GenOway S.A.
      4. Envigo
      5. Taconic Laboratories
      6. Transgenic, Inc.
      7. SAGE Labs
      8. Horizon Discovery
      9. Crown Bioscience Inc.
      10. Harbor Antibodies Bv (A Subsidiary of Harbor BioMed)
      11. Others
      12. References
      13. Related Reports NOTE:
    59. This table of content
    60. is tentative and subject to change as the research progresses.
    61.   In section 12, only the top
    62. companies will be profiled. Each company will be profiled based on the Market Overview
    63. Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.
    64.   Please note: The
    65. financial details of the company cannot be provided if the information is not available
    66. in the public domain and or from reliable sources.  
    67. MODEL MARKET ESTIMATES & FORECAST, 2020–2027 (USD MILLION) MODEL MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) 2020–2027 (USD MILLION) (USD MILLION)
    68. MODEL MARKET, BY REGION, 2020–2027 (USD MILLION) TYPE, 2020–2027 (USD MILLION) 2020–2027 (USD MILLION) (USD MILLION)
    69. ANIMAL MODEL MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION) BY TECHNIQUE, 2020–2027 (USD MILLION) 2020–2027 (USD MILLION) MILLION)
    70. MODEL MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 2020–2027 (USD MILLION) (USD MILLION)
    71. ANIMAL MODEL MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) USERS, 2020–2027 (USD MILLION) (USD MILLION)
    72. MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 2020–2027 (USD MILLION) (USD MILLION)
    73. MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) END USERS, 2020–2027 (USD MILLION) ANIMAL TYPE, 2020–2027 (USD MILLION) TECHNIQUE, 2020–2027 (USD MILLION) 2020–2027 (USD MILLION) (USD MILLION)
    74. ANIMAL MODEL MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) MODEL MARKET, BY APPLICATION, 2020–2027 (USD MILLION) USERS, 2020–2027 (USD MILLION) BY ANIMAL TYPE, 2020–2027 (USD MILLION) BY TECHNIQUE, 2020–2027 (USD MILLION) BY APPLICATION, 2020–2027 (USD MILLION) BY END USERS, 2020–2027 (USD MILLION)   MARKET
    75. 2018 (%)
    76. 2018 (%)
    77. BY COUNTRY, 2018 (%)
    78. BY COUNTRY, 2018 (%)
    79. ANIMAL MODEL MARKET SHARE, BY COUNTRY, 2018 (%) ANALYSIS, 2018 (%)
    80. BV (A SUBSIDIARY OF HARBOUR BIOMED).: SEGMENTAL REVENUE HARBOUR BIOMED).: REGIONAL REVENUE'

    Market Segmentation

    Animal Model Animal Type Outlook (USD Billion, 2018-2030)

    • Pigs
    • Cats
    • Mice

    Animal Model Technology Outlook (USD Billion, 2018-2030)

    • CRISPR
    • Microinjection
    • Embryonic Stem Cell Injection

    Animal Model Application Outlook (USD Billion, 2018-2030)

    • Research and Development
    • Production
    • Quality Control

    Animal Model End User Outlook (USD Billion, 2018-2030)

    • Research Institutes
    • Educational Institutes
    • Pharmaceutical Companies
    • Contract Research Organizations

    Animal Model Regional Outlook (USD Billion, 2018-2030)

    • North America Outlook (USD Billion, 2018-2030)

      • North America Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • North America Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • North America Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • North America Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • US Outlook (USD Billion, 2018-2030)

      • US Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • US Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • US Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • US Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • CANADA Outlook (USD Billion, 2018-2030)

      • CANADA Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • CANADA Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • CANADA Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • CANADA Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
    • Europe Outlook (USD Billion, 2018-2030)

      • Europe Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • Europe Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • Europe Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • Europe Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • Germany Outlook (USD Billion, 2018-2030)

      • Germany Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • Germany Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • Germany Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • Germany Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • France Outlook (USD Billion, 2018-2030)

      • France Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • France Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • France Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • France Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • UK Outlook (USD Billion, 2018-2030)

      • UK Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • UK Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • UK Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • UK Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • ITALY Outlook (USD Billion, 2018-2030)

      • ITALY Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • ITALY Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • ITALY Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • ITALY Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • SPAIN Outlook (USD Billion, 2018-2030)

      • Spain Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • Spain Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • Spain Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • Spain Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • Rest Of Europe Outlook (USD Billion, 2018-2030)

      • Rest Of Europe Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • REST OF EUROPE Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • REST OF EUROPE Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • REST OF EUROPE Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
    • Asia-Pacific Outlook (USD Billion, 2018-2030)

      • Asia-Pacific Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • Asia-Pacific Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • Asia-Pacific Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • Asia-Pacific Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • China Outlook (USD Billion, 2018-2030)

      • China Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • China Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • China Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • China Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • Japan Outlook (USD Billion, 2018-2030)

      • Japan Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • Japan Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • Japan Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • Japan Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • India Outlook (USD Billion, 2018-2030)

      • India Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • India Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • India Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • India Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • Australia Outlook (USD Billion, 2018-2030)

      • Australia Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • Australia Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • Australia Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • Australia Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)

      • Rest of Asia-Pacific Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • Rest of Asia-Pacific Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • Rest of Asia-Pacific Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • Rest of Asia-Pacific Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
    • Rest of the World Outlook (USD Billion, 2018-2030)

      • Rest of the World Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • Rest of the World Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • Rest of the World Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • Rest of the World Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • Middle East Outlook (USD Billion, 2018-2030)

      • Middle East Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • Middle East Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • Middle East Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • Middle East Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • Africa Outlook (USD Billion, 2018-2030)

      • Africa Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • Africa Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • Africa Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • Africa Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
      • Latin America Outlook (USD Billion, 2018-2030)

      • Latin America Animal Model by Animal Type
        • Pigs
        • Cats
        • Mice
      • Latin America Animal Model by Technology
        • CRISPR
        • Microinjection
        • Embryonic Stem Cell Injection
      • Latin America Animal Model by Application
        • Research and Development
        • Production
        • Quality Control
      • Latin America Animal Model by End User
        • Research Institutes
        • Educational Institutes
        • Pharmaceutical Companies
        • Contract Research Organizations
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study

    Smartphone Motherboard Parts Manufacturing Research